APA

Lee E. K., Tan-Wasielewski Z., Aghajanian C., Coleman R. L., Curtis J., Hirsch M. S., Matulonis U. A., Cantley L. C., Mills G. B., Doyle L. A. & Liu J. F. (2020). Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). : Gynecologic oncology reports.

Chicago

Lee Elizabeth K, Tan-Wasielewski Zhenying, Aghajanian Carol, Coleman Robert L, Curtis Jennifer, Hirsch Michelle S, Matulonis Ursula A, Cantley Lewis C, Mills Gordon B, Doyle L Austin and Liu Joyce F. 2020. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). : Gynecologic oncology reports.

Harvard

Lee E. K., Tan-Wasielewski Z., Aghajanian C., Coleman R. L., Curtis J., Hirsch M. S., Matulonis U. A., Cantley L. C., Mills G. B., Doyle L. A. and Liu J. F. (2020). Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). : Gynecologic oncology reports.

MLA

Lee Elizabeth K, Tan-Wasielewski Zhenying, Aghajanian Carol, Coleman Robert L, Curtis Jennifer, Hirsch Michelle S, Matulonis Ursula A, Cantley Lewis C, Mills Gordon B, Doyle L Austin and Liu Joyce F. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). : Gynecologic oncology reports. 2020.